Bridging the Gap Between Innovation and Capital
Pfizer Ventures
Early-stage life science biotech companies developing therapeutics, medical devices or AI
Program
Calling all early stage therapeutic focused biotech companies!
Pfizer Ventures invests in areas of current or future strategic interest to Pfizer with the goal of remaining at the forefront of life science advances. They identify and invest in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’s pipeline and shape the future of the industry.
Event
LaunchBio and Silicon Valley Bank, a division of First Citizens Bank, are pleased to announce their next Investor Connect virtual event with Pfizer Ventures. Pfizer Ventures seeks opportunities within potentially transformative therapeutics, with an emphasis in the core therapeutic areas of: Inflammation & Immunology, Internal Medicine, Oncology, Anti-Infectives, and Vaccines.
Applications will be selected based on meeting the following criteria:
Geography:
Not restricted.
Company type:
Early-stage life science biotech companies developing therapeutics, medical devices or AI.
Milestones anticipated:
- Inflammation & Immunology, Internal Medicine, Oncology, Anti-Infectives, and Vaccines
- Asset-focused therapeutic companies with strong in vivo data.
- Platform-focused therapeutic companies with disruptive technology, to validate and expand platforms and nominate lead assets.
- Companies addressing large unmet medical needs and markets with strong in vivo data, to fund design, manufacturing, and clinical testing.
Stage:
Companies seeking pre-seed, seed, series A and series B funding.
Qualifying start-ups can apply here today. Applications are accepted on a rolling basis.
Learn more about LaunchBio’s Investor Connect series, in partnership with Silicon Valley Bank, a division of First Citizens Bank.